The Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective of 74 HIV/Aids Patient Groups - HIV/Aids Edition

  • ID: 4593510
  • Report
  • 50 pages
  • PatientView
1 of 5
HIV/Aids Patient Groups are Discontented with Pharma Companies-Saying That R&D Would be Better if the Industry Could Understand the Needs of Communities with HIV/Aids

FEATURED COMPANIES

  • Abbvie
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gilead
  • GSK
  • Janssen
  • MORE
  • The views of 74 HIV/AIDS patient groups.
  • Drawn from a November 2017-February 2018 survey.

Still discontented with pharma...

HIV/AIDS patient groups have been among the most forthright and active elements of the patient movement since the days of the founding of the very first of them. Yet, despite the significant improvements in HIV/AIDS treatments made over the decades, feelings of discontent among HIV/AIDS patient groups still exist. The 2017 Corporate-Reputation survey found HIV/AIDS patient groups to be especially critical of the progress that the pharmaceutical industry may (or may not) have made on a whole set of issues, including:

  • integrity
  • transparency in the sharing of clinical-trials data; and
  • patient safety.
  • Underlying these negative sentiments was a real feeling among HIV/AIDS patient groups that people living with HIV/AIDS were increasingly desperate for new products capable of providing a tangible difference to their lives, delivering:
  • higher potentcies in drugs
  • reduced side effects
  • once-daily dosages; and
  • less drug resistance.

On the topic of the industry's ability to innovate in the area of HIV/AIDS, only 46% of the HIV/AIDS patient groups thought pharma to be “Excellent” or “Good” in 2017. To put such a finding in context, 74% of patient groups specialising in haemophilia saw the pharma industry as “Excellent” or “Good” at innovating in the subject area of haemophilia in 2017.

In fact, as few as 31% of 2017's respondent HIV/AIDS patient groups thought that the pharmaceutical industry had an “Excellent” or “Good” corporate reputation that year—a figure well below the 44% reported by HIV/AIDS patient groups in the 2016 survey, and also below the equivalent figure from patient groups therapy wide (43%) in 2017.

... but HIV/AIDS patient groups want better R&D—and think that greater engagement is key to achieving this goal 

Two main themes arising out of HIV/AIDS patient-group comments to the 2017 Corporate-Reputation survey is the wish for pharmaceutical companies to:

  •  actively engage themselves in the communities affected by HIV/AIDS; and
  •  create better channels of communication with HIV/AIDS patient groups.

Comments of this nature were made by HIV/AIDS patient groups from all parts of the world. One compelling reason for such engagement was that HIV/AIDS patient groups felt themselves well equipped to guide pharma’s R&D activities toward products that people living with HIV/AIDS truly need.

So, how did the companies perform at corporate reputation in 2017, in the viewpoints of HIV/AIDS patient groups?

Ranking at corporate reputation is measured by patient groups familiar with a company.

  • ViiV Healthcare ranked overall 1st in 2017 for corporate reputation among HIV/AIDS patient groups familiar with the company. ViiV has now held this rank for five years in a row. ViiV was also 1st in 2017 for eight of the 12 individual indicators of corporate reputation.
  • Gilead came next, ranking overall 2nd. The company was ranked 1st for four of the 12 indicators of corporate reputation.
  • Janssen was ranked overall 3rd. Janssen also had the highest Net Promoter Score (NPS) in the HIV/AIDS element of the 2017 Corporate-Reputation survey: +33.3%.
  • AbbVie ranked overall 4th. And...
  • GSK, which acts on behalf of ViiV in some geographic markets, came 5th.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gilead
  • GSK
  • Janssen
  • MORE

Executive Summary
HIV/Aids Patient-Group Relationships With Pharma, 2017
Industry-Wide Findings From HIV/Aids Patient Groups, 2017
Rankings Of The 10 Pharma Companies, 2017 V. 2016
Among HIV/Aids Patient Groups Familiar With The Companies
Positionings Of Seven Pharma Companies, 2017 V. 2016
Among HIV/Aids Patient Groups That Work/Partner With The Companies
Profiles Of The 10 Companies, 2017

Appendices
I. HIV/Aids Patient Groups: Views On Pharma; And Recommendations For Improvement
II. Profiles Of Respondent HIV/Aids Patient Groups, 2017

Tables and Charts
The Pharma Industry’s Corporate Reputation Over Time, 2013-2017 (According To HIV/Aids Patient Groups)
Companies Ranking 1st For Each Of The 12 Indicators, 2017 (According To HIV/Aids Patient Groups Familiar With The Company)
Number Of HIV/Aids Patient Groups Familiar, And Partnering, With The 10 Companies, 2017
The Types Of Relationships That HIV/Aids Patient Groups Have With Partner Pharmaceutical Companies, 2017
The Corporate Reputation Of The Pharmaceutical Industry, 2017 V. 2016 - Compared With That Of Eight Other Healthcare Sectors (According To HIV/Aids Patient Groups)
The Pharma Industry’S Corporate Reputation Over Time, 2013-2017 (According To HIV/Aids Patient Groups)
HIV/Aids Patient Groups’ Views On The Efficacy Of The Pharmaceutical Industry At The Indicators Of Corporate Reputation, 2017—Chart And Table
HIV/Aids Patient Groups’ Views On The Efficacy Of The Pharmaceutical Industry At The
Indicators Of Corporate Reputation, 2017 V. 2016 V. Patient Groups Of All Therapy Areas, 2017
HIV/Aids Patient Groups’ Views On The Efficacy Of The Pharmaceutical Industry At Various Indicators Of Corporate Reputation, 2017, Compared With The Views Of Patient Groups
From 21 Other Therapy Areas - Analysis By Each Indicator
Rankings Of 10 Individual Pharma Companies, 2017 V. 2016 (According To HIV/Aids Patient Groups Familiar With The Company)
Positionings Of Nine Individual Pharma Companies, 2017 V. 2016 (According To HIV/Aids Patient Groups That Work/Partner With The Company)
Profiles of the 10 Companies, 2017

CHARTS AND TABLES FOR EACH OF THE 10 COMPANIES:

  • Number of HIV/AIDS patient groups claiming familiarity with the company, 2017.
  • Number of HIV/AIDS patient groups saying that they had a working relationship with the company, 2017.
  • Company performance scores among HIV/AIDS patient groups familiar with the company, and which worked with the company, for each of the 12 indicators of corporate reputation, 2017.
  • Percentage of the HIV/AIDS patient groups that worked with the company, but which also worked with other companies, 2017.
  • Profile of respondent HIV/AIDS patient groups familiar with the company, 2017: country headquarters; geographic remit; and types of relationships with the company.
  • The company’s PCRIs (Patient Corporate Reputation Index) for each of the 12 indicators - as assessed by HIV/AIDS patient groups familiar with the company, 2017 v. 2016 v. 2015.
  • Overall rankings for the company, according to HIV/AIDS patient groups familiar with the company, 2017 v. 2016.
  • Overall positionings for the company, according to HIV/AIDS patient groups that work with the company, 2017 v. 2016.
  • Company rankings for each of the 12 indicators according to HIV/AIDS patient groups familiar, or working, with the company, 2017 v. 2016.
  • The company’s Net Promoter Score, 2017, as assessed by HIV/AIDS patient groups that work with the company.
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbvie
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gilead
  • GSK
  • Janssen
  • Merck & Co/MSD
  • Roche
  • Sanofi
  • ViiV Healthcare
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll